Your browser doesn't support javascript.
loading
Omalizumab and allergen immunotherapy for respiratory allergies: A mini-review from the Allergen-Immunotherapy Committee of the Italian Society of Pediatric Allergy and Immunology (SIAIP)
De Filippo, M; Votto, M; Caminiti, L; Carella, F; De Castro, G; Landi, M; Olcese, R; Panasiti, I; Vernich, M; Barberi, S.
Afiliação
  • De Filippo, M; University of Pavia. Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences. Pavia. Italy
  • Votto, M; University of Pavia. Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences. Pavia. Italy
  • Caminiti, L; Department of Pediatrics, Allergy Unit, University of Messina. Messina. Italy
  • Carella, F; Azienza Ospedaliera Universitaria Policlinico Giovanni XXIII. Pediatric Unit. Bari. Italy
  • De Castro, G; Department of Pediatrics, Sapienza University of Rome. Rome. Italy
  • Landi, M; National Research Council. Institute for Biomedical Research and Innovation. Department of Biomedicine. Palermo. Italy
  • Olcese, R; Istituto Giannina Gaslini. Allergy Center. Department of Pediatrics. Genoa. Italy
  • Panasiti, I; Department of Pediatrics, Allergy Unit, University of Messina. Messina. Italy
  • Vernich, M; ASST-Rhodense. Pediatric Unit. Milan. Italy
  • Barberi, S; Casa di cura Villa Montallegro. Allergy Clinic. Genoa. Italy
Allergol. immunopatol ; 50(6): 47-52, 01 nov. 2022. tab
Artigo em Inglês | IBECS | ID: ibc-211523
Biblioteca responsável: ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Although currently approved to treat severe asthma and chronic spontaneous urticaria, omalizumab has also been an effective and safe add-on treatment for other allergic diseases. Namely, omalizumab has been proposed to be used as add-on therapy in patients with allergic rhinitis and asthma and undergoing specific allergen immunotherapy (AIT). AIT is the only treatment that modifies the natural history of IgE-mediated diseases. This brief review summarizes the available evidence and controversies on the efficacy and safety of omalizumab combined with specific AIT (AU)
Assuntos


Texto completo: Disponível Coleções: Bases de dados nacionais / Espanha Base de dados: IBECS Assunto principal: Asma / Alérgenos / Dessensibilização Imunológica / Antiasmáticos / Antialérgicos / Rinite Alérgica / Omalizumab Limite: Humanos Idioma: Inglês Revista: Allergol. immunopatol Ano de publicação: 2022 Tipo de documento: Artigo Instituição/País de afiliação: ASST-Rhodense/Italy / Azienza Ospedaliera Universitaria Policlinico Giovanni XXIII/Italy / Casa di cura Villa Montallegro/Italy / Department of Pediatrics, Allergy Unit, University of Messina/Italy / Department of Pediatrics, Sapienza University of Rome/Italy / Istituto Giannina Gaslini/Italy / National Research Council/Italy / University of Pavia/Italy

Texto completo: Disponível Coleções: Bases de dados nacionais / Espanha Base de dados: IBECS Assunto principal: Asma / Alérgenos / Dessensibilização Imunológica / Antiasmáticos / Antialérgicos / Rinite Alérgica / Omalizumab Limite: Humanos Idioma: Inglês Revista: Allergol. immunopatol Ano de publicação: 2022 Tipo de documento: Artigo Instituição/País de afiliação: ASST-Rhodense/Italy / Azienza Ospedaliera Universitaria Policlinico Giovanni XXIII/Italy / Casa di cura Villa Montallegro/Italy / Department of Pediatrics, Allergy Unit, University of Messina/Italy / Department of Pediatrics, Sapienza University of Rome/Italy / Istituto Giannina Gaslini/Italy / National Research Council/Italy / University of Pavia/Italy
...